P- 112 METABOLIC FATTY LIVER DISEASE: FIBROSIS AND SARCOPENIA FREQUENCIES AND CORRELATION

Abstract

Introduction and Objectives: Fatty liver disease associated with metabolic dysfunction is a global health problem with a prevalence of about 25% worldwide. The measurement of hepatic stiffness by elastography stratifies patients with a greater propensity for cirrhosis in addition to systemic manifestations. This study aimed to estimate liver fibrosis and sarcopenia in patients at risk for metabolic fatty liver disease. Materials and Methods: Selected patients were selected for cross-sectional clinical evaluation. Non-invasive assessment was performed using biomarkers, assessment of APRI and FIB-4, ultrasound and elastography. By ultrassonography 12 % had light steatosis, 12% moderate and the sarcopenia tests used were: self-reported registry, hand grip test and hepatic frailty index (FI) test. Results: Our series of 49 patients was 80.6% female and 19.4% male; mean age of 59 years, mean BMI 32 kg/m²; 28.6% had fibrosis >=2, designated as significant. The elastography average obtained was 9 kpa. Steatosis by the parameter attenuation coefficient (CAP) was not significantly different according to fibrosis. Fibrosis was associated with elevated AST (p value 0.04). ALT and fibrosis were not correlated (p=0.07). The mean value of the FIB-4 was 1.47, while that of the APRI was 0.36. Five patients in our series presented sarcopenia by LFI and there was a correlation with the presence of hepatic fibrosis (p<0.05). Conclusions: Our study showed 28.6% of a quaternary hospital with MAFLD risk had fibrosis by elastography, 31.5% altered FIB-4, and 13.5% altered APRI. Fibrosis by elastography and by the FIB-4 test is more sensitive than APRI. Sarcopenia by liver frailty index was correlated with fibrosis, although other studies are necessary for an accurate conclusion.